GLP1R and breast carcinoma: ASCO guidelines endorse weight management, diet, and exercise to improve quality of life and mitigate treatment related side effects [175, 181] GLP-1 receptor agonists, including semaglutide and liraglutide, have demonstrated clinically meaningful weight loss in breast cancer patients, with studies reporting a 5% mean weight reduction at 12 months and up to 8.89 kg in women with stage I–III disease [182, 183].